SARS-CoV-2 hyperimmune globulin for severely immunocompromised patients with COVID-19: a randomised, controlled, double-blind, phase 3 trial
Sammy Huygens(Ghent University Hospital), Jarom Heijmans(Cancer Center Amsterdam), Quincy Hofsink(Amsterdam Neuroscience), Susanne Bogers(Erasmus MC), Grigorios Papageorgiou(Erasmus MC), Matthijs R. A. Welkers(Amsterdam University Medical Centers), V.M.J. Novotný(Sanquin), Abraham Goorhuis, Arnon P. Kater(Amsterdam University Medical Centers), Bart Rijnders(Erasmus MC), Inger S. Nijhof(St. Antonius Ziekenhuis), Francis Swaneveld(Sanquin), Peter A. te Boekhorst(Erasmus MC)
Cited by 1
Related Papers
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.6k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Cross-sectional Comparison of the Prevalence of Age-Associated Comorbidities and Their Risk Factors Between HIV-Infected and Uninfected Individuals: The AGEhIV Cohort Study
|Clinical Infectious Diseases|2014|773
Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data
|The Lancet|2018|733
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630